0
Original Research: PULMONARY HYPERTENSION |

Efficacy of Bosentan in a Small Cohort of Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease*

Raymond L. Benza, MD; Barry K. Rayburn, MD; Jose A. Tallaj, MD; Christopher S. Coffey, PhD; Laura J. Pinderski, MD, PhD; Salpy V. Pamoukian, MD; Robert C. Bourge, MD
Author and Funding Information

*From the Departments of Medicine (Drs. Benza, Rayburn, Tallaj, Pinderski, Pamoukian, and Bourge) and Biostatistics (Dr. Coffey), University of Alabama at Birmingham, Birmingham, AL.

Correspondence to: Raymond L. Benza, MD, Tinsley Harrison Towers, Room 328A, 1900 University Blvd, Birmingham, AL 35294-0006; e-mail: rbenza@uab.edu



Chest. 2006;129(4):1009-1015. doi:10.1378/chest.129.4.1009
Text Size: A A A
Published online

Objectives: This study was designed to assess the tolerability and efficacy of the oral endothelin receptor antagonist bosentan in adult patients with pulmonary arterial hypertension (PAH) related to congenital heart disease (CHD).

Background: Severe PAH in the setting of CHD is a debilitating syndrome for which there are limited treatment options. This is the first long-term study experience in adults reporting on the tolerability and efficacy of therapy with bosentan for this patient population.

Methods: A 12-month single-center experience with 19 women and 5 men with PAH associated with CHD (79% in New York Heart Association [NYHA] class III) was analyzed. Hemodynamic responses, exercise capacity, and Borg dyspnea index were assessed prior to the administration of bosentan, and again at 3, 6, and 12 months after the study began. Clinical assessments were performed monthly for up to 12 months. The change from baseline was tested using the Wilcoxon pairs test.

Results: There was significant improvement in hemodynamics from baseline to 12 months (mean [± SD] systolic pulmonary arterial pressure, 99 ± 30 to 87 ± 28 mm Hg [p ≤ 0.001]; mean pulmonary arterial pressure, 60 ± 18 to 52 ± 17 mm Hg [p ≤ 0.001]; mean right atrial pressure, 12 ± 6 to 8 ± 5 mm Hg [p ≤ 0.001]; mean pulmonary vascular resistance, 663 ± 386 to 504 ± 307 dyne · s · cm−5 [p < 0.01]; pulmonary capillary wedge pressure, 15 ± 5 to 11 ± 3 mm Hg [p < 0.001]). NYHA functional class also improved from baseline to 12 months (NYHA class I/II range, 17 to 71%; p < 0.001). There was a marginally significant trend toward improvement in the mean 6-min walk test distance at 12 months (299 ± 85 to 330 ± 95 m; p = 0.05). Three patients needed to discontinue bosentan therapy because of elevated liver function test results. There were no deaths or hospitalizations, and no significant change in arterial oxygen saturation had occurred at 12 months.

Conclusions: Bosentan therapy improved hemodynamics and NYHA class in patients with PAH that was associated with CHD. These effects were seen after 3 to 6 months. Bosentan therapy may provide an effective alternative to current therapies in this patient population.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543